 Apellis Pharmaceuticals Incs NASDAQ: APLS pegcetacoplan posted mixed results in two Phase 3 trials in 1,258 geographic atrophy GA. Despite the mixed showing, CEO Cedric Francois thinks the candidates performance was strong enough to warrant an FDA nod. 